Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

2 terminated/withdrawn out of 10 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

20%

2 trials in Phase 3/4

Results Transparency

0%

0 of 8 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
6(60.0%)
Phase 3
2(20.0%)
Phase 1
2(20.0%)
10Total
Phase 2(6)
Phase 3(2)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials
NCT01973504Phase 2Withdrawn

Phase 2c Dose Comparison Study of MP4OX in Trauma

Role: lead

NCT01925001Phase 2Withdrawn

Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis

Role: lead

NCT01262196Phase 2Completed

Phase IIb Study of MP4OX in Traumatic Hemorrhagic Shock Patients

Role: lead

NCT00494949Phase 1Completed

Increasing Dose Safety Study of Hemospan in Orthopedic Surgery Patients

Role: lead

NCT01356485Phase 1Completed

Safety Study of MP4CO in Adult Sickle Cell Patients

Role: lead

NCT00633659Phase 2Completed

Pilot Study of Hemospan® in Patients With Chronic Critical Limb Ischemia

Role: lead

NCT01004198Phase 2Completed

Phase IIa Study of MP4OX in Traumatic Hemorrhagic Shock Patients

Role: lead

NCT00420277Phase 3Completed

Phase III Study of Hemospan® for Treating Hypotension in Hip Arthroplasty

Role: lead

NCT00425334Phase 2Completed

Safety Study of Hemospan® in Prostatectomy Patients

Role: lead

NCT00421200Phase 3Completed

Phase III Study of Hemospan® to Prevent Hypotension in Hip Arthroplasty

Role: lead

All 10 trials loaded